Filing summary
Entity discrepancy: The request identifies Alaunos Therapeutics, Inc., but the supplied Form 10-Q is for ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). This summary reflects the filing provided, not an Alaunos filing. The report covers the unaudited quarter and six months ended June 30, 2019; it was signed August 8, 2019.
Business context and reporting period
ZIOPHARM was a clinical-stage immuno-oncology company developing Sleeping Beauty cell-therapy and Controlled IL-12 gene-therapy programs. It had no recurring operating revenue and had operated at a loss since inception. Its fiscal year ends December 31.
Key financial metrics
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Collaboration revenue | $0 | $0 | $0 | $0.146 million |
| Research and development expense | $9.998 million | $7.489 million | $19.474 million | $17.672 million |
| General and administrative expense | $4.755 million | $4.889 million | $8.900 million | $11.048 million |
| Total operating expenses | $14.753 million | $12.378 million | $28.374 million | $28.720 million |
| Net loss | $14.620 million | $12.031 million | $28.054 million | $28.051 million |
| Basic and diluted loss per share | $0.09 | $0.12 | $0.17 | $0.27 |
At June 30, 2019, cash and cash equivalents were $43.563 million, total current assets $65.859 million, current liabilities $10.400 million, and working capital $55.459 million (the MD&A separately reports $56.5 million, so the filing contains an apparent inconsistency). Total liabilities were $11.178 million; the filing reports lease liabilities but no borrowings or other financial debt. Accumulated deficit was $594.383 million. No meaningful operating margin is available because the company had no Q2 revenue.
For the first six months, operating cash use was $18.319 million, investing cash use $0.077 million, and financing cash provided $0.230 million; cash declined $18.166 million to $43.563 million. The filing does not provide a clear standalone Q2 cash-flow figure.
Material changes versus prior comparable period
- Q2 R&D expense rose $2.509 million (34%), mainly reflecting NCI patent-license payments and increased nonclinical cell-therapy work. First-half R&D increased $1.802 million (10%), including higher cell- and gene-therapy manufacturing and research costs, partly offset by reduced CD33 program activity and other expenses.
- First-half G&A fell $2.148 million (19%), primarily because the 2018 period included higher consulting costs and stock-option modification expense. Q2 G&A was broadly flat year over year.
- First-half net loss was essentially unchanged from 2018, while Q2 net loss increased $2.589 million. The prior-year comparison included preferred-stock dividends that increased loss applicable to common shareholders; those dividends were absent in 2019.
- Operating cash use improved to $18.319 million from $29.131 million, affected in part by working-capital movements, including use of prepaid resources at MD Anderson. Cash and cash equivalents fell from $61.729 million at year-end 2018.
- The company adopted lease accounting Topic 842 on January 1, 2019, recognizing approximately $1.6 million of right-of-use assets and lease liabilities, with no material income-statement impact.
Outlook, developments and risks
- Management estimated that June 30 cash, together with approximately $45 million gross proceeds from a July 2019 warrant-exercise private placement, would fund planned operations into the first half of 2021. The proceeds were subsequent to quarter-end; the company said it had no other committed sources of capital and expected to need additional financing for longer-term plans.
- The July transaction involved exercise of warrants for 15,015,152 shares at $3.01 per share and issuance of new warrants for up to 15,015,152 additional shares at $7.00. It provides cash but creates potential dilution. A separate $100 million ATM facility had been established in June; no shares had been sold under it by the filing date.
- In July, the Eden BioCell joint venture with TriArm closed. TriArm committed up to $35 million and is to manage clinical development of Sleeping Beauty CD19 CAR-T therapies in China, Taiwan and Korea.
- Clinical updates included FDA clearance of the NCI-sponsored Sleeping Beauty neoantigen TCR trial IND, enrollment in a Phase 2 Controlled IL-12 plus cemiplimab trial for recurrent glioblastoma, and expansion of the Phase 1 Controlled IL-12 plus nivolumab trial. The company also reported FDA Fast Track designation for Controlled IL-12 in recurrent or progressive glioblastoma. These are development milestones, not proof of efficacy or approval.
- The company expects continuing losses and substantial development spending. Management cautioned that actual cash needs could exceed forecasts and that inability to raise funds or secure partnerships could require program delays, reductions or discontinuation.
- Material execution risks include early-stage clinical evidence and small trial populations, regulatory uncertainty, safety and efficacy outcomes, manufacturing and supply constraints, competition, dependence on licensed intellectual property and collaborators, and possible dilution from future fundraising. The filing reported no legal matters believed likely to have a material adverse effect as of June 30, 2019.
- Contractual obligations reported at June 30 totaled $13.118 million, including operating leases, the NCI CRADA and royalty/license fees. The NCI patent license also entails milestone, royalty and sublicense obligations that could arise in the future.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is ZIOPHARM Oncology, Inc., not Alaunos Therapeutics, Inc.
- Check the July 2019 private placement’s closing, net proceeds after expenses, share issuance and warrant terms, and resulting dilution.
- Assess whether the cash runway estimate through the first half of 2021 remains valid against actual spending, clinical timelines and financing needs.
- Track trial enrollment, safety and efficacy results, regulatory developments, and whether interim clinical findings are confirmed by later data.
- Reconcile the filing’s working-capital figures: balance-sheet amounts imply approximately $55.5 million, while MD&A states $56.5 million.
- Review material license, CRADA, lease and future milestone obligations, along with any changes in partner funding or development responsibilities.